復星醫藥(600196.SH):子公司擬以1.41億美元受讓重慶復創23.9992%股權
格隆匯12月31日丨復星醫藥(600196.SH)公佈,2021年12月31日,公司控股子公司復星醫藥產業與Weibo Wang簽訂《股權轉讓協議》,復星醫藥產業擬現金出資1.41億美元受讓WeiboWang持有的重慶復創23.9992%的股權(對應實繳註冊資本342.9萬美元)。本次轉讓完成後,復星醫藥產業及其控股子公司江蘇萬邦、重慶醫工院將合計持有重慶復創100%股權。
重慶復創由集團與Weibo Wang於2009年創設,Weibo Wang及重慶復創科學家團隊在小分子藥物的早期發現、構建和設計方面具備優勢能力,經過十多年的發展,重慶復創已自主研發了一批主要針對腫瘤、代謝類疾病的在研藥物,且上述在研藥物已大部分進入臨牀階段,取得了階段性成果。
本次轉讓完成後,集團將持續以豐富的臨牀註冊能力和產業化資源推進重慶復創在研藥物的後續臨牀、註冊和商業化。此外,集團擬與Weibo Wang(及科學家團隊)另行設立新公司繼續開展小分子藥物研發領域的合作,具體安排(包括但不限於註冊資本金等)待各方進一步協商確定,公司將根據最終確定的合作方案履行相應的程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.